Host: Mimi Secor, DNP, FNP-BC, FAANP 


Guest: James B, Potash, MD, MPH 



  Psychopharmacology is the study of genetic variations to pinpoint more effective personalized treatments for psychiatric disorders. But with clinicians, industry heads, insurance providers, and regulating agencies all weighing in on this practice and forming varying opinions, what’s the best way to move forward? Here to answer that question and others with Dr. Mimi Secor is Dr. James Potash, a Professor of Psychiatry and Behavioral Sciences and Psychiatrist in Chief at the John Hopkins Department of Psychiatry. 

Genetic Testing for Psychiatric Disorders: Is It Ready for Primetime?

Tune in to interviews with the top thought leaders in medicine exploring the clinical and professional issues that are foremost in the minds of the medical community. Join us at the Clinician's Roundtable for discussions on a vast range of topics that every medical professional should know about.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

Host: Charles Turck, PharmD, BCPS, BCCCP 


  Guest: Melanie Dispenza, MD 



  
    The future therapeutic landscape for food allergy prevention is looking clearer as a drug typically used to treat hematologic malignancies has shown to prevent systemic anaphylaxis to allergens and increase patients' tolerance to peanuts. Along with this, other therapies are also in development for allergy treatment. To learn more, join Dr. Charles Turck as he dives deeper into this study and its findings with Dr. Melanie Dispenza, Assistant Professor of Medicine at Johns Hopkins University School of Medicine.

Preventing Allergic Reactions to Peanuts with a Cancer Drug

Host: Charles Turck, PharmD, BCPS, BCCCP 


  Guest: Henry Rosenberg, MD 



  
    Malignant hyperthermia is an inherited disorder primarily recognized by anesthesia professionals. And since this condition can have significant consequences on a patient’s health, including their likelihood of surviving surgery, it’s important to know how to diagnose and treat malignant hyperthermia emergencies in operating room settings. Join Dr. Charles Turck as he dives deeper into this topic with Dr. Henry Rosenberg, a member of the Board of Directors of the Malignant Hyperthermia Association of the United States.

Navigating the Crisis: How to Diagnose and Treat Malignant Hyperthermia

Host: Matt Birnholz, MD 


  Guest: Donald Kohn, MD 



  
    Third-generation lentiviral vectors were developed to improve upon safety measures and mitigate the risks of toxicity and replication that are typically associated with first- and second-generation therapies. These advancements may help enhance the functionality and utility of third-generation lentiviral vectors in various gene therapy applications. Learn more about the development, efficacy, and safety of third-generation lentiviral vectors with Dr. Matt Birnholz and Dr. Donald Kohn, Distinguished Professor at the University of California, Los Angeles. This non-certified educational series is produced and controlled by ReachMD, and is intended for healthcare professionals only. 

Evolving Gene Therapy: A Deep Dive into 3rd-Generation Lentiviral Vectors

Host: Charles Flexner, MD 



  
    Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner is a Professor of Medicine of Pharmacology, Molecular Sciences, and International Health at Johns Hopkins University, and he also presented a session on this exact topic at the 2024 Conference on Retroviruses and Opportunistic Infections.

Innovations in Adherence: Long-Acting Agents for Infectious Diseases

Host: Charles Turck, PharmD, BCPS, BCCCP 


  Guest: Prithviraj  Bose, MD 



  
    Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individualized treatment plan as this could have a significant positive impact on their quality of life and outcome. To learn more, dive in with Dr. Charles Turck as he speaks with Dr. Prithvi Bose, Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center. 

Genetic Testing for Psychiatric Disorders: Is It Ready for Primetime?

Download our free app to listen on your phone